Outgoing Merck CEO Touts COVID Innovations, But Worries Pandemic Prep May Lack Staying Power
Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.
You may also be interested in...
US FDA is open to keeping COVID-necessitated trial changes that may have had unexpected benefits. The agency is also looking at building on pandemic’s focus on health disparities and inequities to push for more generalizable and inclusive clinical trial designs.
Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.